MYC and diffuse large B-cell lymphoma: In phase I and II clinical studies, the efficacy of treatment with CUDC-907 was evaluated in patients with R/R DLBCL, with ORR of 18.1%, a CR rate of 8.6%, and a PR rate of 9.5% after one cycle of treatment, compared to the patients bearing MYC mutation with ORR of 23.3%, a CR rate of 13.3%, and a PR rate of 10% (51).